Bayer to acquire 100% stake in its joint venture with Zydus

3 May 2024 , 01:25 PM

Bayer is set to acquire full ownership of its joint venture with Zydus Lifesciences Ltd (formerly Cadila Healthcare), known as Bayer Zydus Pharma Private Limited (BZPPL). Initially established as a 50:50 joint venture on January 28, 2011, BZPPL was formed with the purpose of selling and marketing pharmaceutical products in India.

Over time, Bayer increased its ownership stake to 75% in the joint venture. The acquisition of the remaining 25% stake will allow Bayer to gain complete control over BZPPL, in accordance with the pre-agreed terms of the joint venture.

Shweta Rai, Managing Director of Bayer’s Pharmaceuticals division for India and Country Division Head for South Asia, expressed appreciation for Zydus Lifesciences as a valuable partner in their joint mission of introducing innovative health solutions and addressing healthcare needs in India.

Rai emphasized Bayer’s commitment to maintaining a strong presence in India and continuing its mission of providing health solutions for all. 

BZPPL’s focus has primarily been on prescription products, particularly in cardiology and women’s healthcare, as well as specialty therapeutics in areas such as oncology, hematology, and ophthalmology, as stated on its website.

For feedback and suggestions, write to us at [e-mail]